Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue 1
Submit an article Journal homepage
896
Views
19
CrossRef citations to date
0
Altmetric
Oncology

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer

Nicole PrincicIBM Watson Health, Cambridge, MA, USA; Correspondence[email protected]
,
Ayal AizerBrigham and Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Cambridge, MA, USA;
,
Derek H. TangNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA;
,
David M. SmithIBM Watson Health, Cambridge, MA, USA;
,
William JohnsonIBM Watson Health, Cambridge, MA, USA;
&
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, Cambridge, MA, USA
Pages 73-80 | Received 06 Jul 2018, Accepted 31 Aug 2018, Published online: 20 Sep 2018

References

  • American Cancer Society. Breast cancer facts & figures 2015–2016. ACS. Atlanta, Georgia; 2015. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2015-2016.pdf [Last accessed 1 March 2018]
  • Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106:dju055
  • Vera-Llonch M, Weycker D, Glass A, et al. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 2011;11:250
  • Lage MJ, Borker R, Barber B, et al. Healthcare costs in postmenopausal women with hormone-positive metastatic breast cancer. J Med Econ 2010;13:691-7
  • Mariotto A, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 2017;26:809-15
  • Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35
  • Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-39
  • Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19
  • Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in patients with HR+/HER2– advanced breast cancer who progressed on endocrine therapy. J Clin Oncol 2017;35:2875-84
  • Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer (Version 2). NCCN; Harborside Press LLC. 2016. Available at: http://www.nccn.com [Last accessed 1 March 2018]
  • Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012;8:651-7
  • Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 2012;366:520-9
  • Condorelli R, Spring L, O’Shaughnessy J, et al. Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol 2018;29:640-5
  • Yang C, Li Z, Bhatt T, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene 2017;36:2255-64
  • Tang DH, Li N, Du EX, et al. First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study. Curr Med Res Opin 2017;33:2137-43
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiology 1992;45:613-19
  • Reinert T, Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol 2015;7:304-20
  • Brufsky A. Long-term management of patients with hormone receptor-positive metastatic breast cancer: concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev 2017;59:22-32
  • Burton T, Dacosta Byfield S, Fan Y, et al. Patient characteristics, clinical and economic outcomes of women with first-line therapy for HR+/HER2– metastatic breast cancer in a large US managed care health plan: chemotherapy first vs. no chemotherapy first. Cancer Res 2015;75(9 Suppl):Abstract nr P3-07-23
  • Song Y, Hao Y, Macalalad AR, et al. Clinical outcomes with first-line endocrine therapy or chemotherapy in postmenopausal HR+/HER2− metastatic breast cancer. Breast Cancer (Auckl) 2015;9:67-72

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.